The COVID-19 vaccines currently being administered, or considered, in the MENA region

Over the past month, a number of COVID-19 vaccines have been approved for general or emergency use in the Middle East and North Africa (MENA). In our previous article, we looked at the main 4 types of vaccine – and the pros and cons of each one.

Now, using data collated by the Vaccine Centre at the London School of Hygiene & Tropical Medicine, along with various regional government media statements, we bring you a roundup of the actual COVID-19 vaccines currently circulating in the MENA. The most common ones at the moment, in no particular order, are by Sinopharm, Sinovac, Pfizer-BioNTech, Moderna, Oxford-AstraZeneca, and Sputnik V (Gamaleya Research Institute). Here’s what’s known about them.

Editor’s note: Information is accurate at time of publishing; however, given the ongoing updates in research – plus possible changes in governmental decisions – the availability and reliability of these vaccines is subject to change at any time.



Sinopharm (Beijing Institute of Biological Products)

Total number in registered trials: 56,128

Efficacy data: 79% in a press release; no supporting details reportedly provided

Storage requirements: Refrigeration (2°C to 8°C)

Manufacture projections: No official information; up to 1 billion doses in